Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
122.87
+0.87 (0.71%)
At close: Aug 13, 2025, 4:00 PM
127.00
+4.13 (3.36%)
After-hours: Aug 13, 2025, 7:59 PM EDT
Insmed Employees
Insmed had 1,271 employees as of December 31, 2024. The number of employees increased by 359 or 39.36% compared to the previous year.
Employees
1,271
Change (1Y)
359
Growth (1Y)
39.36%
Revenue / Employee
$313,222
Profits / Employee
-$813,801
Market Cap
25.97B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,271 | 359 | 39.36% |
Dec 31, 2023 | 912 | 176 | 23.91% |
Dec 31, 2022 | 736 | 123 | 20.07% |
Dec 31, 2021 | 613 | 92 | 17.66% |
Dec 31, 2020 | 521 | 86 | 19.77% |
Dec 31, 2019 | 435 | 62 | 16.62% |
Dec 31, 2018 | 373 | 159 | 74.30% |
Dec 31, 2017 | 214 | 53 | 32.92% |
Dec 31, 2016 | 161 | 36 | 28.80% |
Dec 31, 2015 | 125 | 36 | 40.45% |
Dec 31, 2014 | 89 | 28 | 45.90% |
Dec 31, 2013 | 61 | 20 | 48.78% |
Dec 31, 2012 | 41 | -1 | -2.38% |
Dec 31, 2011 | 42 | 2 | 5.00% |
Dec 31, 2010 | 40 | 25 | 166.67% |
Dec 31, 2009 | 15 | -82 | -84.54% |
Dec 31, 2008 | 97 | 3 | 3.19% |
Dec 31, 2007 | 94 | -63 | -40.13% |
Dec 31, 2006 | 157 | 72 | 84.71% |
Dec 31, 2005 | 85 | 30 | 54.55% |
Dec 31, 2004 | 55 | 35 | 175.00% |
Dec 31, 2003 | 20 | -3 | -13.04% |
Dec 31, 2002 | 23 | -37 | -61.67% |
Dec 31, 2001 | 60 | 20 | 50.00% |
Dec 31, 2000 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
INSM News
- 1 day ago - FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease - Benzinga
- 1 day ago - US FDA approves Insmed's lung disease drug - Reuters
- 1 day ago - FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease - PRNewsWire
- 6 days ago - Insmed Incorporated (INSM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts - Seeking Alpha
- 6 days ago - Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 14 days ago - Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains. - Barrons
- 20 days ago - Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025 - PRNewsWire